PHarmacological Audit study of Safety and Effectiveness in Real world: Naldemedine for Opioid-Induced Constipation study
Not Applicable
- Conditions
- opioid-induced constipation
- Registration Number
- JPRN-UMIN000031381
- Lead Sponsor
- ational Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1) patients with suspected malignant bowel obstruction, or previous history of malignant bowel obstruction and high recurrence risk 2) prior naldemedine administration
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Spontaneous bowel movements within 24 hours after first naldemedine administration
- Secondary Outcome Measures
Name Time Method umber of spontaneous bowel movements during 1 week after first naldemedine administration